Recruiting Schizophrenia Studies in San Diego
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia....
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder....
Randomized Withdrawal Study in Patients With Schizophrenia
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia...
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants age...
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults....
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
This is an outpatient, single center, between-group, double blind, placebo controlled design. Approximately 120 adolescents and adult patients will be randomized to either have their treatment augment...
About Schizophrenia Clinical Trials in San Diego
Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.
There are currently 6 schizophrenia clinical trials recruiting participants in San Diego, CALIFORNIA. These studies are seeking a combined 2,404 participants. Research is being sponsored by Neurocrine Biosciences, Intra-Cellular Therapies, Inc., Vanda Pharmaceuticals and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Schizophrenia Clinical Trials in San Diego — FAQ
Are there schizophrenia clinical trials in San Diego?
Yes, there are 6 schizophrenia clinical trials currently recruiting in San Diego, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in San Diego?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Diego research site will contact you about next steps.
Are clinical trials in San Diego free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Diego studies also compensate for your time and travel.
What schizophrenia treatments are being tested?
The 6 active trials in San Diego are testing new therapies including novel drugs, biologics, and treatment approaches for schizophrenia.
Data updated March 2, 2026 from ClinicalTrials.gov